Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2014

01.02.2014 | short review

Treatment and clinical results in childhood AML in Greece

verfasst von: Dr. Sofia Polychronopoulou, Dr. Margarita Baka, Dr. Marina Servitzoglou, Dr. Vasilios Papadakis, Dr. Apostolos Pourtsidis, Dr. Georgia Avgerinou, Dr. Mirella Abatzidou, Dr. Helen Kosmidis

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The primary objective of our study is to describe the clinical results of children with AML, treated with BFM protocols, in two institutions in Greece.

Patients and methods

Between January 1997 and December 2011, 84 children with primary and secondary AML were treated with BFM AML 93, 98 and 2004 protocol and were eligible for evaluation.

Results

Median follow-up for survivors was 86.3 months. The most usual cytogenetic abnormalities t(8;21), t(15;17) and Myeloid/Lymphoid (MLL) rearrangement were detected in eight, six, and nine children respectively. Out of the 73 patients with primary AML, three died before completion of first induction. Only one has never responded to chemotherapy and eight patients had M2 or M3 bone marrow after induction and required more than one courses to achieve remission. On the whole, 46/70 (65.7 %) patients are alive, in remission. Out of 24 patients who suffered from relapse, only seven are alive in second remission. The event-free survival in standard and high risk group was 17/21 (80.9 %) and 31/52 (59.6 %), respectively, with the difference being statistically significant.

Conclusions

The major cause of mortality in children with AML in our institutions was recurrence of disease. Supportive care, molecular features of the disease, and response to therapy are increasingly used to optimize treatment for all patients.
Literatur
1.
Zurück zum Zitat Woods W. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 2006;46:565–69.PubMedCrossRef Woods W. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 2006;46:565–69.PubMedCrossRef
2.
Zurück zum Zitat Pession A, Massetti R, Rizarri C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170–8.PubMedCrossRef Pession A, Massetti R, Rizarri C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170–8.PubMedCrossRef
4.
Zurück zum Zitat Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies. Klin Padiatr. 2013;225(Suppl 1):p. 79–86. Creutzig U, Zimmermann M, Dworzak MN, et al. Development of a curative treatment within the AML-BFM studies. Klin Padiatr. 2013;225(Suppl 1):p. 79–86.
5.
Zurück zum Zitat Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from Children’s Oncology Group. Blood. 2013;121(18):3573–7.PubMedCrossRef Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from Children’s Oncology Group. Blood. 2013;121(18):3573–7.PubMedCrossRef
6.
Zurück zum Zitat O’Brien T, Russell S, Vowels M, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group. Blood. 2002;100:2708–16.PubMedCrossRef O’Brien T, Russell S, Vowels M, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group. Blood. 2002;100:2708–16.PubMedCrossRef
7.
Zurück zum Zitat Lange B, Smith F, Feusner J, et al. Untreated pediatric acute myeloid leukemia: a report from the children’s outcomes in CCG-2961, a children’s oncology group phase 3 trial for oncology group. Blood. 2009;111:1044–53.CrossRef Lange B, Smith F, Feusner J, et al. Untreated pediatric acute myeloid leukemia: a report from the children’s outcomes in CCG-2961, a children’s oncology group phase 3 trial for oncology group. Blood. 2009;111:1044–53.CrossRef
8.
Zurück zum Zitat Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–52.PubMedCentralPubMedCrossRef Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–52.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Kaspers G, Zwaan C. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Hematologica. 2007;92:1519–32.CrossRef Kaspers G, Zwaan C. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Hematologica. 2007;92:1519–32.CrossRef
10.
Zurück zum Zitat de Botton SC, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22(8):1404–12.PubMedCrossRef de Botton SC, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22(8):1404–12.PubMedCrossRef
11.
Zurück zum Zitat Sanz M, Grimwade D, Tallman M, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.PubMedCrossRef Sanz M, Grimwade D, Tallman M, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.PubMedCrossRef
12.
Zurück zum Zitat Manola KN, Panitsas F, Polychronopoulou S, et al. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet. 2013;206(3):63–72.PubMedCrossRef Manola KN, Panitsas F, Polychronopoulou S, et al. Cytogenetic abnormalities and monosomal karyotypes in children and adolescents with acute myeloid leukemia: correlations with clinical characteristics and outcome. Cancer Genet. 2013;206(3):63–72.PubMedCrossRef
13.
Zurück zum Zitat Harrison C, Hills R, Moorman A, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRef Harrison C, Hills R, Moorman A, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRef
14.
Zurück zum Zitat von Neuhoff CR, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–9.CrossRef von Neuhoff CR, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–9.CrossRef
15.
Zurück zum Zitat Kavcic M, Fisher BT, Li Y, et al. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer. 2013;119(10):1916–23.PubMedCrossRef Kavcic M, Fisher BT, Li Y, et al. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer. 2013;119(10):1916–23.PubMedCrossRef
16.
Zurück zum Zitat Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicaemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113(2):376–82.PubMedCrossRef Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicaemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113(2):376–82.PubMedCrossRef
17.
Zurück zum Zitat Johannsen KH, Handrup MM, Lausen B, Schrøder H, Hasle H. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer. 2013;60(7):1154–60.PubMedCrossRef Johannsen KH, Handrup MM, Lausen B, Schrøder H, Hasle H. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer. 2013;60(7):1154–60.PubMedCrossRef
18.
Zurück zum Zitat Creutzig U, van den Heuvel-Eibrink M, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205.PubMedCrossRef Creutzig U, van den Heuvel-Eibrink M, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205.PubMedCrossRef
19.
Zurück zum Zitat Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499–506.PubMedCrossRef Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24(27):4499–506.PubMedCrossRef
20.
21.
Zurück zum Zitat Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205–14.PubMedCrossRef Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205–14.PubMedCrossRef
22.
Zurück zum Zitat Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30(29):3625–32.PubMedCentralPubMedCrossRef Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30(29):3625–32.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Pui C, Carroll W, Meshinchi S, Arceci R. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–65.PubMedCentralPubMedCrossRef Pui C, Carroll W, Meshinchi S, Arceci R. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–65.PubMedCentralPubMedCrossRef
Metadaten
Titel
Treatment and clinical results in childhood AML in Greece
verfasst von
Dr. Sofia Polychronopoulou
Dr. Margarita Baka
Dr. Marina Servitzoglou
Dr. Vasilios Papadakis
Dr. Apostolos Pourtsidis
Dr. Georgia Avgerinou
Dr. Mirella Abatzidou
Dr. Helen Kosmidis
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0112-x

Weitere Artikel der Ausgabe 1/2014

memo - Magazine of European Medical Oncology 1/2014 Zur Ausgabe